All In Biotech

Drug Trial Radar · NCT00036556

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Aug 15, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 941 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

941

Actual

Start

Jun 2001

Primary completion

Not stated

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
May 13, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Male only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

  • AtrasentanDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-to-disease progression will be determined by the time to onset of the earliest of one of the following events: New skeletal lesions, new metastatic extra-skeletal lesions, or an event due to metastatic prostate cancer.Time frame: Every 12 weeks

Locations

234 sites in 17 countries. Site status is shown where the registry gives one.

  • Urology Centers Of Alabama

    Homewood, Alabama

  • Alaska Clinical Research Center, LLC

    Anchorage, Alaska

  • Advanced Clinical Trials

    Tucson, Arizona

  • Arkansas Urologial Associates, PA

    Little Rock, Arkansas

  • Robin V. Smith, MD

    Chula Vista, California

  • Urology Associate Of Central California

    Fresno, California

  • South Valley Medical Plaza

    Gilroy, California

  • San Diego Urology Center

    La Mesa, California

  • South Orange County Medical Research Center

    Laguna Hills, California

  • UCLA School of Medicine

    Los Angeles, California

  • VA Palo Alto

    Palo Alto, California

  • Hillcrest Urological Medical Group, Inc.

    San Diego, California

  • Urology Associates Of San Luis Obispo

    San Luis Obispo, California

  • Pacific Clinical Research

    Santa Monica, California

  • Western Clinical Research, Inc.

    Torrance, California

  • Urology Associate, Pc

    Denver, Colorado

  • South Fl Medical Research

    Aventura, Florida

  • Clinical Physiology Associates

    Fort Myers, Florida

  • Advanced Research Institute

    New Port Richey, Florida

  • Dattoli Cancer Center

    Sarasota, Florida

  • Urology Treatment Center

    Sarasota, Florida

  • Southeastern Urological Center, P.A.

    Tallahassee, Florida

  • Peachtree Hematology/Oncology Consultants

    Atlanta, Georgia

  • Emory Clinic

    Atlanta, Georgia

  • Sandy Springs Urology

    Atlanta, Georgia

  • Atlanta Va Medical Center

    Decatur, Georgia

  • Dreyer Medical Clinic

    Aurora, Illinois

  • Northwestern University Medical School

    Chicago, Illinois

  • Progressive Care, S.C.

    Chicago, Illinois

  • Christopher Ryan, MD

    Chicago, Illinois

  • Weiss Memorial Hospital

    Chicago, Illinois

  • Evanston Hospital Kellogg Cancer Center

    Evanston, Illinois

  • Welborn Clinic

    Evansville, Indiana

  • Welborn Clinic -East

    Evansville, Indiana

  • Urologic Associates, Pc

    Davenport, Iowa

  • Iowa Urology

    Des Moines, Iowa

  • Kansas University Medical Center

    Kansas City, Kansas

  • Regional Urology

    Shreveport, Louisiana

  • LSUHSC

    Shreveport, Louisiana

  • Johns Hopkins Oncology Center

    Baltimore, Maryland

Showing 40 of 234 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.